Microscopic polyangiitis (MP) is a rare systemic disease belonging to the group of vascular inflammatory processes characterized by damage to small and medium-sized vessels. The disease manifests itself as vasculitis, which mainly affects the kidneys, lungs, skin and peripheral nerves. Microscopic polyangiitis may be associated with the presence of antiphospholipid syndrome, and is most often associated with positive tests for antineutrophil cytoplasmic antibodies (ANCA), in particular the myeloperoxidase type (MPO-ANCA). These antibodies are the main marker in diagnosis.
History of the disease and interesting historical facts
Microscopic polyangiitis was first described in 1994, but its proven association with vasculitis was known much earlier. Evidence of pathological changes in small vessels can be found in the works of scientists such as Rudolf Virchow, who in the 19th century formulated the principle that “all diseases begin with the vessels”. In the 1970s, the first studies were conducted on the role of ANCA in the pathogenesis of this disease. Interestingly, early studies emphasized the need to distinguish between microscopic polyangiitis and granulomatosis with polyangiitis (Wegener's disease), since they may have similar clinical manifestations, but differ in morphological and immune aspects.
Epidemiology
Statistics on the disease show that microscopic polyangiitis occurs in approximately 3-10 cases per 1,000,000 population per year. According to studies, there has been a slight increase in the incidence in recent years, which may be due to increased awareness among doctors and improved diagnostic methods. The peak incidence is observed in the age group from 50 to 70 years, and the disease affects men and women equally. Differences in ethnic groups have also not been identified, however, the results of some studies show higher rates among the white population compared to people of other racial groups.
Genetic predisposition to this disease
To date, studies have not provided clear evidence of a hereditary predisposition to microscopic polyangiitis. However, a number of genes involved in the immune response and inflammatory processes continue to be studied. The main focus is on genes associated with HLA (histocompatibility, major complex), including HLA-DRB1 and associated variations, which may increase the risk of developing the disease. Some studies point to possible mutations in genes regulating cytokine production and angiogenesis, but without a clear link to preferential heredity.
Risk factors for the development of this disease
There are several risk factors that may hypothetically contribute to the development of microscopic polyangiitis:
- Environmental factors: Exposure to toxic chemicals such as pesticides and solvents may increase the risk of disease.
- Infectious agents: Certain viral and bacterial infections, particularly streptococcal and viral, have been reported to be associated with a high risk of vasculitis.
- Drug allergies: Reactions to certain drugs, such as antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), can also serve as a trigger.
- Comorbidities: Having rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune diseases may increase the likelihood of developing MP.
Diagnosis of this disease
The main symptoms of microscopic polyangiitis range from mild to severe and may include:
- Hematuria and proteinuria are changes in urine tests that indicate renal involvement.
- Coughing up blood and shortness of breath are symptoms that indicate pulmonary pathology.
- Skin rashes including purpura and ulcers.
- Neurological signs: peripheral neuropathy and other neurological symptoms.
Laboratory tests typically include:
- Complete blood count for anemia and inflammatory markers.
- Immunological tests for ANCA (a positive result is often key to diagnosis).
- Kidney biopsy to confirm the diagnosis of vasculitis.
Radiological tests, such as chest X-rays and CT scans, can help detect changes in the lungs.
Differential diagnosis includes other types of vasculitis, such as granulomatosis with polyangiitis and cryoglobulinemic vasculitis, as well as infectious and neoplastic diseases.
Treatment
Treatment for microscopic polyangiitis is aimed at controlling inflammation and organ damage. General approaches may include:
- Pharmacological treatment: The focus is on the use of corticosteroids and immunosuppressants such as cyclophosphamide, methotrexate and azathioprine.
- Surgical treatment: In cases where kidney failure develops, dialysis or a kidney transplant may be required.
- Use of biologics: Newer treatments such as rituximab are becoming increasingly popular for treating severe forms of the disease.
List of medications used to treat this disease
- Corticosteroids (prednisolone).
- Cyclophosphamide.
- Methotrexate.
- Azathioprine.
- Rituximab.
Disease monitoring
Monitoring of patients with microscopic polyangiitis includes regular check-ups to assess the effectiveness of therapy and the degree of disease activity. The prognosis of the disease depends on the time of diagnosis and the adequacy of treatment. Approximately 80% patients show positive dynamics with proper treatment, while the rest may develop renal failure or other serious complications.
Age-related features of the disease
The course of microscopic polyangiitis can vary significantly depending on the age group:
- In older people, the disease may manifest itself more acutely and with a high risk of developing serious complications.
- In younger patients, the manifestations are less pronounced, but may require a longer course of treatment.
- In children, the disease occurs much less frequently, and the clinical picture is often less pronounced with the possibility of self-resolution.
Questions and Answers
- What is microscopic polyangiitis?
Microscopic polyangiitis is a vasculitis affecting small and medium-sized vessels that most commonly affects the kidneys and lungs, often associated with ANCA. - What are the main symptoms of the disease?
Symptoms include hematuria, proteinuria, pulmonary manifestations (coughing up blood), skin rashes, and neurologic abnormalities. - How is microscopic polyangiitis diagnosed?
Diagnosis is based on clinical examination, laboratory tests for ANCA, organ biopsy and radiography. - How is microscopic polyangiitis treated?
It is treated with immunosuppressive therapy, including steroids and drugs based on cyclophosphamide and new biological agents. - What is the prognosis for patients with microscopic polyangiitis?
The prognosis depends on the time of diagnosis and treatment; timely and adequate intervention can ensure a good degree of remission.
Thus, microscopic polyangiitis is a serious disease that requires a careful approach to both diagnosis and treatment in order to minimize the risk of complications and improve the quality of life of patients.
